Clinical trials: Rhabdoviridae Infections
Rabies
Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
This study was planned to establish the non-inferiority of Rabipur administered as simulated post exposure Zagreb schedule as compared to Essen schedule, in healthy Indian adult subjects.
- Trial name
- NCT01365494
- Testing
- Purified Chick Embryo Cell Inactivated Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rabies, Rabies Virus
Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine
This study is designed to gather safety and immunogenicity data with Purified Vero Rabies Vaccine - Serum Free (VRVg), when given in a post-exposure prophylaxis vaccination schedule, using the Essen regimen, across different…
- Trial name
- NCT01339312
- Testing
- Purified inactivated rabies vaccine, serum free, Purified Vero Rabies Vaccine
- Where
- China
- Volunteers
- 816 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults
The purpose of this study is to generate data in human on immunogenicity and safety of Purified Vero Rabies Vaccine (VRVg) in support of the vaccine registration.
- Trial name
- NCT00948272
- Testing
- Purified Vero Rabies Vaccine - Serum Free, Purified inactivated rabies vaccine
- Where
- 6 sites in France
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Years
The safety of different immunization procedures of rabies vaccine (human diploid cells) was investigated by successive design of different age groups.
- Trial name
- NCT06132789
- Testing
- Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Influenza-like Illness, Upper Respiratory Disease
Non-specific Effects of Rabies Vaccine
Vaccines work by stimulating the body to produce a high-quality, rapid and specific immune response upon exposure to infection by a particular disease-causing microorganism - the microorganism targeted by the vaccine.
- Conditions
- Influenza-like Illness, Upper Respiratory Disease, Diarrhea, Fever
- Trial name
- NCT03656198
- Testing
- Rabivax-S, Sterile Water Injection
- Where
- Saint Kitts and Nevis
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Ross University School of Veterinary Medicine
Rabies
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
This is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP).
- Trial name
- ARPEP (NCT03961555)
- Testing
- SYN023, HRIG (HyperRab), Rabies vaccine
- Where
- 14 sites in United States, Philippines
- Volunteers
- 448 people
- Sponsor
- Synermore Biologics Co., Ltd.
Rabies
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen
The aim of the study is to document the safety and immunogenicity of Purified Vero Rabies Vaccine (VRVg) when given in a simulated post-exposure regimen, i.e.
- Trial name
- NCT01877395
- Testing
- Purified Vero Rabies Vaccine (VRVg), Imovax® Rabies: inactivated rabies vaccine
- Where
- 5 sites in United States
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Immunogenicity and Safety of Verorab™ in Indian Population
To demonstrate that rabies vaccine administered according to the Thai Red Cross, (TRC)-ID regimen (2-2-2-0-1-1) is not inferior to rabies vaccine administered according to the ESSEN IM regimen in terms of Geometric Mean Titers…
- Trial name
- NCT00260351
- Testing
- Purified Verocell Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 405 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
An Expanded Access Program for SYN023 in Rabies Treatment
This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected…
- Trial name
- NCT07706907
- Testing
- Zamerovimab and Mazorelvimab Injection
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Rabies (Healthy Volunteers)
A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody
A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects
- Trial name
- NCT07445815
- Testing
- Recombinant Human Rabies Virus Monoclonal Antibody Injection, Human Rabies Immunoglobulin (HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Rabies
A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) or placebo in combination with rabies vaccine in…
- Trial name
- NCT00656097
- Testing
- CL184, HRIG
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Rabies
Adherence to Anti-rabies Post-exposure Prophylactic Protocols
This study aims to investigate physicians' adherence to Advisory Committee on Immunization Practices (ACIP) guidelines regarding Anti-rabies post-exposure prophylaxis in Egypt.
- Trial name
- NCT07012083
- Testing
- survey
- Where
- Egypt
- Volunteers
- 214 people
- Sponsor
- Tanta University
Rabies
Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly
An open label, non-comparative bridging study to evaluate the safety of Rabies vaccine INDIRAB® in Healthy Vietnamese volunteer aged from 5 years old.
- Trial name
- NCT02729168
- Testing
- Human rabies vaccine
- Where
- Vietnam
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products
Rabies
Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen
The purpose of this study is to assess the 4-site "one-week" post-exposure prophylaxis (PEP) regimen as a possible alternative to the 2-site updated Thai Red Cross (TRC) PEP regimen.
- Trial name
- NCT01622062
- Testing
- PVRV, PVRV and pERIG Favirab®
- Where
- Philippines
- Volunteers
- 600 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen
This study will evaluate the immunogenicity of rabies vaccine at 13 months, 3 year and 5 years after initial vaccination, administered in two different post-exposure vaccination schedules
- Trial name
- NCT01067079
- Testing
- No vaccine administered; subjects only have blood sampling for immunogenicity
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rabies (Healthy Volunteers)
Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.
A multicentre, open label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens (2 x 1IM regimen, 2 x 2 ID regimen, 1 x 2 ID regimen) when administering a single-dose…
- Trial name
- BAZOOKA_221 (NCT07455318)
- Testing
- Booster vaccination
- Where
- 6 sites in Belgium
- Volunteers
- 561 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Rabies
Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response
No study was conducted to evaluate the rabies neutralizing antibody titers after RIG injection on day 7. The only study that has supported the delay of RIG administration was done in 1996 by our institute, of which RIG was given…
- Trial name
- NCT03524417
- Testing
- Equine rabies immunoglobulin injection on day 7
- Where
- Thailand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Rabies, Rabies Immunisation
Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
This is a single-center, observer-blinded, dosage-escalation trial to evaluate the safety, tolerability, reactogenicity, and immunogenicity of ChAd155-RG compared with RABAVERT in rabies virus-naïve healthy male and non-pregnant…
- Trial name
- NCT04019444
- Testing
- ChAd155-RG, Rabies Vaccine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rabies, Japanese Encephalitis
Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers
This study evaluated the safety and immunogenicity of rabies vaccine and Japanese encephalitis vaccine in toddlers. All children developed adequate immune responses.
- Conditions
- Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis
- Trial name
- NCT00694460
- Testing
- Three 1 mL doses of Rabies vaccine and two JE vaccine, Three 0.5 mL doses of Rabies vaccine and two JE vaccine, Three 0.1mL doses of Rabies Vaccine and two JE vaccine
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis
Rabies Virus Infection
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people
- Trial name
- NCT06548139
- Testing
- Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg, Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg, Rabies Human Immunoglobulin (HRIG)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.